Navigation Links
VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
Date:1/7/2008

in the third quarter of 2008 from this study.

The CEA study is designed to evaluate the efficacy of VIA-2291 in the vessel wall, and has the unique advantage of providing access to atherosclerotic tissue for direct evaluation of VIA-2291's effect on inflammation, through a panel of assays and histological examinations.

Acute Coronary Syndrome (ACS) Study

The ACS study has enrolled more than two-thirds of the targeted 200 patients for this trial and top-line data results are anticipated to be released shortly after the release of data from the CEA trial. This study is designed to establish dose and safety data in patients with acute coronary syndrome (ACS) who have experienced a recent heart attack, and includes measures of leukotrienes, biomarkers of inflammation as well as medical imaging of the coronary vessel wall to evaluate impact on plaque characteristics.

About VIA-2291

VIA-2291 is a selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). Potentially a complement to current standard of care therapies that treat risk factors, such as statins, antiplatelet and blood pressure medications, VIA-2291 is initially targeted to address the secondary prevention market for patients who have already suffered a major adverse cardiovascular event, but eventually could be beneficial to the broader 15.8 million patients in the U.S. who have coronary artery disease. VIA has exclusive worldwide rights to develop and commercialize VIA-2291. Based upon prior trials of VIA-2291 in more than 1,100 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovas
'/>"/>

SOURCE VIA Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
(Date:12/24/2014)... 2014  Lockton Dunning Benefits, the ... the addition of Vice President Kim Foerster ... Pharmacy Consulting team, Excelsior Solutions. ... to the position.  Most recently, she worked as ... Specialty Pharmacy, where she has held various managerial ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Oct. 1 VirtualScopics, Inc. (Nasdaq: VSCP ), ... revenues for the third quarter ended September 30, 2010 exceeded ... comparable period in 2009 and a greater than 9% growth ... increased over 30% for the period ended September 30, 2010 ...
... 1 Palatin Technologies, Inc. (NYSE Amex: PTN ... Annual BIO Investor Forum on Wednesday, October 6, 2010 at ... the 9th Annual BIO Investor Forum will take place October ... Carl Spana, Ph.D., President and Chief Executive Officer ...
Cached Medicine Technology:VirtualScopics Revenues Hit Another Quarterly Record 2VirtualScopics Revenues Hit Another Quarterly Record 3
(Date:12/25/2014)... December 25, 2014 BambooFlooringChina.com sells many ... quality bamboo flooring. Today, the company announces big ... many styles and colors. , BambooFlooringChina.com is the world’s ... the promotion is valid until Jan. 20, 2015. , ... and woven with a natural thread. All the bamboo ...
(Date:12/25/2014)... When head lice hits a home or ... to get rid of it while keeping it from taking ... now have the solution right in their neighborhood: Lice ... Troopers provides full spectrum head lice screening and treatment services ... Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Very sick children with complex chronic illnesses can receive effective, ... "medical home," with easy access to a team of dedicated ... less likely to become seriously ill and need either hospitalization ... treatment at an enhanced medical home clinic at the University ...
(Date:12/25/2014)... (HealthDay News) -- Overeating is common during the holidays, but ... an expert says. "Don,t arrive at a party hungry. ... know you,ll be attending a party, but deprivation leads to ... at Northern Westchester Hospital in Mount Kisco, N.Y., said in ... during the day and even to have a snack before ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
Breaking Medicine News(10 mins):Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3
... National Institutes of Health grant will help University of ... the damage caused by multiple sclerosis and other neurological ... College of Medicine and a member of UCF,s Hybrid ... a four-year, $1.9 million project. His team will study ...
... individualized therapy and better supportive care helped push the ... 71 percent three years after diagnosis, according to new ... and reported in the medical journal The Lancet ... 20 percent better than previously reported U.S. rates and ...
... with dyslexia often struggle with reading, writing, and spelling, ... in other areas. New neurological research has found that ... to structural differences within an important information highway in ... language. The findings are published in the June 2010 ...
... ... Zvetco Biometrics today announced that its Verifi™ line of fingerprint biometric readers will secure ... and Mental Hygiene , ... (PRWEB) May 8, 2010 -- Zvetco Biometrics , a leader in fingerprint ...
... private insurance pays greater share today , MONDAY, May 10 ... States almost doubled between 1987 and 2005, with private insurers taking ... , Researchers led by Florence Tangka, a health economist at ... 1987 to that from 2001 to 2005. In 1987, the total ...
... ... is now available at SleepHappens.com. , ... (PRWEB) May 10, 2010 -- Mattress Warehouse is proud to announce ... Collection is exclusive to Mattress Warehouse and features unique BeautyStyle aesthetics and BeautyFeel support ...
Cached Medicine News:Health News:$1.9 million grant to help UCF find multiple sclerosis 'nerve-ana' 2Health News:Smarter use of existing treatment helps dramatically boost survival of young AML patients 2Health News:Differences in language circuits in the brain linked to dyslexia 2Health News:Zvetco Biometrics Delivers Needed Authentication for New York City Department of Health and Mental Hygiene 2Health News:Zvetco Biometrics Delivers Needed Authentication for New York City Department of Health and Mental Hygiene 3Health News:Mattress Warehouse Announces Its New Simmons Mattress Lineup 2
... Used for catheter positioning and exchange in ... the wire guide coils allows utilization of ... smooth transition to a very flexible tip. ... is the most rigid coiled wire guide ...
Supplied sterile in peel-open packages. Intended for one-time use....
... Used as an initial access wire into ... prior to an endourology procedure. The mandril type ... that of a .035 inch (0.89 mm) diameter ... guide is of spring coil construction over the ...
Used for percutaneous nephrostomy. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: